Brian Van Tine, MD, PhD, on Progress and Challenges With Cell Therapy for Sarcoma

News
Video

The professor of medicine and pediatrics at Washington University in St. Louis discussed the current investigative landscape for cell therapy in treating sarcomas.

“We've learned that there's issues with cytokine release syndrome, which is why this has to be given impatient by people that know what they're doing. But compared to getting chemothearpy once every 3 weeks, it's much safer and much better tolerated in the long term. And so, we're really trying to spread the message that everybody should know their (HLA) status. I think as these become more prevalent, and the targets become more available, hopefully everybody will eventually have access to something like this.”

July was Sarcoma Awareness Month and CGTLive spoke with Brian Van Tine, professor, medicine and pediatrics, Washington University in St. Louis, to learn more about the current state of therapy in the disease, recent progress in the field, and challenges that still remain. Van Tine discussed accessibility challenges that persist despite novel cell therapies coming closer to market, namely human leukocyte antigen restrictions for most therapies in development. He shared his belief that more doors will soon open in terms of targets for cell therapies.

Van Tine serves as investigator on the SPEARHEAD-1 trial (NCT04044768) assessing afamitresgene autoleucel (afami-cel; AdaptImmune) T-cell receptor SPEAR T-cell therapy in patients with advanced synovial sarcoma (SS) and myxoid/round cell liposarcoma. The trial most recently demonstrated a survival benefit in patients with advanced SS and Van Tine presented these data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting, held June 2-6, in Chicago, Illinois.

REFERENCE
Van Tine BA, Ganjoo KN, Blay JY, et al. The SPEARHEAD-1 trial of afamitresgeneautoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma. Presented at: ASCO 2023 Annual Meeting; June 2-6; Chicago, Illinois. Poster #497
Related Videos
Paula Cannon, PhD, the president elect of ASGCT and a distinguished professor of microbiology at Keck School of Medicine of USC
George Tachas, PhD
Alexandra Gomez-Arteaga, MD
Pietro Genovese, PhD, the principal investigator at the Gene Therapy Program of Dana-Farber/Boston Children’s Cancer and Blood Disorder Center
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
© 2024 MJH Life Sciences

All rights reserved.